ASH 2018 | The MAIA study and other myeloma highlights from ASH 2018
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Gareth Morgan, MD, PhD, FRCP, FRCPath, of the UAMS Myeloma Institute, Little Rock, AR, discusses the Phase III MAIA study (NCT02252172) that’s underway to further establish the role of daratumumab in the treatment of transplant-ineligible newly diagnosed multiple myeloma (NDMM). Prof. Morgan also shares his view on the highlights for myeloma from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up